Stockholders’ Equity (Details) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 09, 2022 |
Feb. 07, 2022 |
Oct. 05, 2021 |
Jun. 11, 2021 |
Jun. 08, 2021 |
Jul. 31, 2022 |
Jun. 30, 2022 |
May 31, 2022 |
Apr. 30, 2022 |
Mar. 22, 2022 |
Mar. 22, 2022 |
Mar. 18, 2022 |
Jan. 29, 2021 |
Jan. 25, 2021 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Jun. 30, 2021 |
Jun. 30, 2022 |
Jun. 30, 2021 |
Dec. 31, 2021 |
Nov. 05, 2021 |
Aug. 05, 2021 |
Dec. 31, 2018 |
|
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||||||||||
Common stock, authorized (in Shares) | 116,666,667 | 116,666,667 | 116,666,667 | 116,666,667 | |||||||||||||||||||
Common stock par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||||||
Common stock, shares issued (in Shares) | 42,623,283 | 42,623,283 | 42,623,283 | 40,990,604 | |||||||||||||||||||
Common stock, shares outstanding (in Shares) | 42,623,283 | 42,623,283 | 42,623,283 | 40,990,604 | |||||||||||||||||||
Preferred stock, shares (in Dollars per share) | $ 10,000,000 | $ 10,000,000 | $ 10,000,000 | $ 10,000,000 | |||||||||||||||||||
Preferred stock, par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||||||||
Preferred stock, authorized (in Shares) | 5,000,000 | 5,000,000 | 5,000,000 | 5,000,000 | |||||||||||||||||||
Certificate of designation series A preferred stock (in Shares) | 5,000,000 | 5,000,000 | |||||||||||||||||||||
Public offering, description | On June 11, 2021, pursuant to the 2021 Public Offering, the Company issued 7,360,000 shares of Common Stock (2021 Firm Shares and 2021 Option Shares) at a public price of $7.00 for net proceeds to the Company of $47,523,569 after deducting the underwriting discount and offering fees and expenses payable by the Company. | the Company entered into an underwriting agreement (the “2021 Underwriting Agreement”) with Oppenheimer & Co. Inc., acting as the representative for the underwriters identified therein (the “Underwriters”), relating to the Company’s public offering (the “2021 Public Offering”) of 6,400,000 shares (the “2021 Firm Shares”) of the Company’s Common Stock. Pursuant to the 2021 Underwriting Agreement, the Company also granted the Underwriters a 30-day option to purchase up to an additional 960,000 shares of Common Stock (the “2021 Option Shares,” and together with the 2021 Firm Shares, the “2021 Shares”) to cover over-allotments.The Underwriters agreed to purchase the 2021 Firm Shares from the Company with the option to purchase the 2021 Option Shares at a price of $6.51 per share. The 2021 Shares were offered, issued, and sold pursuant to the Form S-3 and accompanying prospectus filed with the SEC under the Securities Act of 1933 as amended (“Securities Act”). | |||||||||||||||||||||
Option shares at price per share (in Dollars per share) | $ 6.51 | $ 6.51 | $ 6.51 | ||||||||||||||||||||
Common stock, shares issued (in Shares) | 7,360,000 | ||||||||||||||||||||||
Net proceeds | $ 7 | $ 2,360,000 | $ 1,200,000 | $ 2,500,000 | |||||||||||||||||||
Deducting the underwriting discount | $ 47,523,569 | ||||||||||||||||||||||
Sales amount | $ 50,000,000 | ||||||||||||||||||||||
Percentage of gross proceeds | 3.00% | ||||||||||||||||||||||
ATM shares (in Shares) | 337,859 | 171,775 | 343,045 | ||||||||||||||||||||
Sales average price (in Dollars per share) | $ 7.12 | $ 7.19 | $ 7.49 | 7.12 | $ 7.12 | ||||||||||||||||||
Compensation paid by agent | $ 110,428 | $ 37,242 | $ 77,421 | ||||||||||||||||||||
Warrants outstanding to purchase an aggregate (in Shares) | 3,305,854 | ||||||||||||||||||||||
Options term | 4 years 9 months | ||||||||||||||||||||||
Weighted average exercise price (in Dollars per share) | $ 8.53 | $ 8.53 | $ 8.53 | ||||||||||||||||||||
Aggregate of purchase shares (in Shares) | 3,015 | ||||||||||||||||||||||
Stock options vest over period | fouryear | two-year | fouryear | ||||||||||||||||||||
Stock options to purchase common stock description | The actual number of shares subject to the award is determined at the end of the performance period and may range from zero to 100% of the target shares granted depending upon the terms of the award. | ||||||||||||||||||||||
Stock options to purchase shares (in Shares) | 1,248,000 | 3,141,098 | |||||||||||||||||||||
Compensation expense related to non-vested options | $ 3,612,189 | ||||||||||||||||||||||
Weighted-average period | 4 years 8 months 26 days | ||||||||||||||||||||||
Stock based compensation | $ 531,450 | $ 190,357 | $ 864,093 | $ 287,519 | |||||||||||||||||||
Restricted stock (in Shares) | 13,900 | 14,800 | |||||||||||||||||||||
Restricted stock units | 90,563 | 181,126 | |||||||||||||||||||||
Unrecognized compensation expense | 181,126 | ||||||||||||||||||||||
Compensation committee, description | the Compensation Committee approved the grants of 6,362 restricted stock units for each of Ondas’ directors (Messrs. Cohen, Reisfield, Silverman, Seidl, Bushey and Sood). Each restricted stock unit represents a contingent right to receive one share of common stock of the Company. These restricted stock units vest in four successive equal quarterly installments with the first vesting date commencing on the first day of the next calendar quarter, provided that such director is a director of the Company on the applicable vesting dates. The compensation expense recognized in the three- and six-months ended June 30, 2022 in respect of these restricted stock units was $90,563 and $181,126, and as of June 30, 2022 the unrecognized compensation expense was $181,126.On August 5, 2021, the Company entered into employment agreements and awarded 1,375,000 restricted stock units pursuant to the 2018 Plan to key members of American Robotics’ management. Each restricted stock unit represents a contingent right to receive one share of common stock of the Company. The restricted stock units vest in three successive equal annual installments with the first vesting date commencing on the first anniversary of the award date and are contingent on continuing employment. The compensation expense recognized in the three- and six-months ended June 30, 2022 in respect of these restricted stock units was $889,016 and $1,761,750, and as of June 30, 2022 the unrecognized compensation expense was $7,483,365. On January 25, 2021, the Compensation Committee approved the following grants: (a) for Messrs. Cohen, Reisfield and Silverman (i) 5,000 restricted stock units pursuant to the 2018 Plan, and (b) for Mr. Seidl and Ms. Sood (i) 5,000 restricted stock units pursuant to the 2018 Plan, and (ii) 10,000 restricted stock units pursuant to the 2018 Plan. Each restricted stock unit represents a contingent right to receive one share of common stock of the Company. The 5,000 restricted stock units granted to each of Messrs. Cohen, Reisfield, Silverman and Seidl and Ms. Sood vest in four successive equal quarterly installments with the first vesting date commencing on the first day of the next calendar quarter, provided that such director is a director of the Company on the applicable vesting dates. The 10,000 restricted stock units granted to Mr. Seidl and Ms. Sood vest in eight successive equal quarterly installments with the first vesting date commencing on the first day of the next calendar quarter, provided that such director is a director of the Company on the applicable vesting dates. All restricted stock units granted to these directors shall vest in full immediately upon a change in control. The Company recognized stock-based compensation of $31,800 and $63,600 for the three- and six-months ended June 30, 2022. As of June 30, 2022, the unrecognized compensation expense was $63,600. | ||||||||||||||||||||||
Restricted stock units description | the Company entered into employment agreements and awarded 1,375,000 restricted stock units pursuant to the 2018 Plan to key members of American Robotics’ management. Each restricted stock unit represents a contingent right to receive one share of common stock of the Company. The restricted stock units vest in three successive equal annual installments with the first vesting date commencing on the first anniversary of the award date and are contingent on continuing employment. The compensation expense recognized in the three- and six-months ended June 30, 2022 in respect of these restricted stock units was $889,016 and $1,761,750, and as of June 30, 2022 the unrecognized compensation expense was $7,483,365.On January 25, 2021, the Compensation Committee approved the following grants: (a) for Messrs. Cohen, Reisfield and Silverman (i) 5,000 restricted stock units pursuant to the 2018 Plan, and (b) for Mr. Seidl and Ms. Sood (i) 5,000 restricted stock units pursuant to the 2018 Plan, and (ii) 10,000 restricted stock units pursuant to the 2018 Plan. Each restricted stock unit represents a contingent right to receive one share of common stock of the Company. | ||||||||||||||||||||||
Equity Incentive Plan [Member] | |||||||||||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||||||||||
Common stock reserved for issuance (in Shares) | 3,333,334 | ||||||||||||||||||||||
Restricted Stock Units (RSUs) [Member] | |||||||||||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||||||||||
Restricted stock units | 7,288 | ||||||||||||||||||||||
Unrecognized compensation expense | 74,619 | $ 99,124 | |||||||||||||||||||||
Restricted Stock Units (RSUs) [Member] | Minimum [Member] | |||||||||||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||||||||||
Restricted stock units | 5,723 | ||||||||||||||||||||||
Restricted Stock Units (RSUs) [Member] | Maximum [Member] | |||||||||||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||||||||||
Restricted stock units | $ 6,633 | ||||||||||||||||||||||
Certain employees.[Member] | |||||||||||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||||||||||
Aggregate of purchase shares (in Shares) | 216,500 | 135,000 | |||||||||||||||||||||
Certain non-employees [Member] | |||||||||||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||||||||||
Aggregate of purchase shares (in Shares) | 65,000 | ||||||||||||||||||||||
Two non-employees [Member] | |||||||||||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||||||||||
Aggregate of purchase shares (in Shares) | 210,000 | ||||||||||||||||||||||
ATM Offering [Member] | |||||||||||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||||||||||
Net proceeds | $ 650,000 | ||||||||||||||||||||||
ATM shares (in Shares) | 11,995 | ||||||||||||||||||||||
Sales average price (in Dollars per share) | $ 5.62 | ||||||||||||||||||||||
Compensation paid by agent | $ 1,844 | ||||||||||||||||||||||
Equity Incentive Plan [Member] | |||||||||||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||||||||||
Common stock reserved for issuance (in Shares) | 6,000,000 | 6,000,000 | 6,000,000 | ||||||||||||||||||||
Restricted Stock Units (RSUs) [Member] | |||||||||||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||||||||||
Compensation committee grants (in Shares) | 6,362 | ||||||||||||||||||||||
Investor [Member] | Securities Purchase Agreement [Member] | Over-Allotment Option [Member] | |||||||||||||||||||||||
Stockholders’ Equity (Details) [Line Items] | |||||||||||||||||||||||
Description of transaction | the Company filed a shelf Registration Statement on Form S-3 for up to $150,000,000 with the SEC (the “Form S-3”) for shares of its Common Stock; shares of its preferred stock, which the Company may issue in one or more series or classes; debt securities, which the company may issue in one or more series; warrants to purchase its Common Stock, preferred stock or debt securities; and units. The Form S-3 was declared effective by the SEC on February 5, 2021. |